Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging - PubMed (original) (raw)
Clinical Trial
. 2015 Feb 28;6(6):4496-504.
doi: 10.18632/oncotarget.2883.
Anish Thomas 2, Stephen Adler 3, Esther Mena 4, Karen Kurdziel 1, Julia Maltzman 5, Bruce Wallin 5, Kimberly Hoffman 5, Ira Pastan 6, Chang Hum Paik 7, Peter Choyke 1, Raffit Hassan 2
Affiliations
- PMID: 25756664
- PMCID: PMC4414206
- DOI: 10.18632/oncotarget.2883
Clinical Trial
Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging
Liza Lindenberg et al. Oncotarget. 2015.
Abstract
Amatuximab is a chimeric high-affinity monoclonal IgG1/k antibody targeting mesothelin that is being developed for treatment of mesothelin-expressing cancers. Considering the ongoing clinical development of amatuximab in these cancers, our objective was to characterize the biodistribution, and dosimetry of 111Indium (111In) radiolabelled amatuximab in mesothelin-expressing cancers. Between October 2011 and February 2013, six patients including four with malignant mesothelioma and two with pancreatic adenocarcinoma underwent Single Photon Emission Computed Tomography-Computed Tomography (SPECT/CT) imaging following administration of 111In amatuximab. SPECT/CT images were obtained at 2-4 hours, 24-48 hours and 96-168 hours after radiotracer injection. In all patients, tumor to background ratios (TBR) consistently met or exceeded an uptake of 1.2 (range 1.2-62.0) which is considered the minimum TBR that can be visualized. TBRs were higher in tumors of patients with mesothelioma than pancreatic adenocarcinoma. 111In-amatuximab uptake was noted in both primary tumors and metastatic sites. The radiotracer dose was generally well-tolerated and demonstrated physiologic uptake in the heart, liver, kidneys and spleen. This is the first study to show tumor localization of an anti-mesothelin antibody in humans. Our results show that 111In-amatuximab was well tolerated with a favorable dosimetry profile. It localizes to mesothelin expressing cancers with a higher uptake in mesothelioma than pancreatic cancer.
Conflict of interest statement
Conflicts of interest
JM, BW and KH are employees of Morphotek, Inc. The other authors have no conflicts of interest.
Figures
Figure 1. Tumor to background ratios (mean and standard deviation) at 2–4 hours, 24–48 hours and at 96–168 hours after 111In amatuximab for patients with mesothelioma and pancreatic adenocarcinoma
Figure 2. Representative images showing tumor localization of 111In amatuximab and tumor expression of mesothelin in a 53 year old man with metastatic mesothelioma
CT (A), SPECT (B) and SPECT/CT (C) fusion image at 24 hours post-injection of 111In amatuximab showing focal uptake in the left iliac node (indicated by the red arrow). (D) Representative immunohistochemical staining of tumor from left inguinal lymph showing strong membranous and cytoplasmic staining for mesothelin in all tumor cells. Mesothelin staining is indicated by brown staining of tumor cells (20 X magnification).
Figure 3. Representative images showing tumor localization of 111In amatuximab and tumor expression of mesothelin in a 70 year old man with mesothelioma
CT (A), SPECT (B) and SPECT/CT (C) fusion image at 24 hours post-injection of 111In amatuximab showing mild uptake in the right pleural-based mass (arrows). High uptake in the liver, aorta and spleen are physiologic. The increased uptake at the skin level on the left side is the standard vial containing 111Indium. (D) Representative immunohistochemical staining of tumor from right pleural mass showing strong membranous and cytoplasmic staining for mesothelin in > 90% of tumor cells. Mesothelin staining is indicated by brown staining of tumor cells (20 X magnification).
Similar articles
- Evaluation of (111)In labeled antibodies for SPECT imaging of mesothelin expressing tumors.
Misri R, Saatchi K, Ng SS, Kumar U, Häfeli UO. Misri R, et al. Nucl Med Biol. 2011 Aug;38(6):885-96. doi: 10.1016/j.nucmedbio.2011.02.013. Epub 2011 Apr 21. Nucl Med Biol. 2011. PMID: 21843785 - Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
Lee JH, Kim H, Yao Z, Lee SJ, Szajek LP, Grasso L, Pastan I, Paik CH. Lee JH, et al. Nucl Med Biol. 2015 Nov;42(11):880-6. doi: 10.1016/j.nucmedbio.2015.07.008. Epub 2015 Jul 29. Nucl Med Biol. 2015. PMID: 26307499 Free PMC article. - Tumor-Shed Antigen Affects Antibody Tumor Targeting: Comparison of Two 89Zr-Labeled Antibodies Directed against Shed or Nonshed Antigens.
Lee JH, Kim H, Yao Z, Szajek LP, Grasso L, Kim I, Paik CH. Lee JH, et al. Contrast Media Mol Imaging. 2018 Mar 12;2018:2461257. doi: 10.1155/2018/2461257. eCollection 2018. Contrast Media Mol Imaging. 2018. PMID: 29720923 Free PMC article. - Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Hassan R, et al. J Clin Oncol. 2016 Dec;34(34):4171-4179. doi: 10.1200/JCO.2016.68.3672. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27863199 Free PMC article. Review. - Amatuximab and novel agents targeting mesothelin for solid tumors.
Baldo P, Cecco S. Baldo P, et al. Onco Targets Ther. 2017 Nov 8;10:5337-5353. doi: 10.2147/OTT.S145105. eCollection 2017. Onco Targets Ther. 2017. PMID: 29184420 Free PMC article. Review.
Cited by
- Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies.
Benloucif A, Meyer D, Balasse L, Goubard A, Danner L, Bouhlel A, Castellano R, Guillet B, Chames P, Kerfelec B. Benloucif A, et al. Front Immunol. 2023 Jun 14;14:1200652. doi: 10.3389/fimmu.2023.1200652. eCollection 2023. Front Immunol. 2023. PMID: 37388728 Free PMC article. - NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects.
Nicolaides NC, Kline JB, Grasso L. Nicolaides NC, et al. PLoS One. 2023 May 17;18(5):e0285161. doi: 10.1371/journal.pone.0285161. eCollection 2023. PLoS One. 2023. PMID: 37195923 Free PMC article. - Antibody-Based Approaches to Target Pancreatic Tumours.
Sorbara M, Cordelier P, Bery N. Sorbara M, et al. Antibodies (Basel). 2022 Jul 12;11(3):47. doi: 10.3390/antib11030047. Antibodies (Basel). 2022. PMID: 35892707 Free PMC article. Review. - Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors.
Zhang GZ, Li TF, Han SY. Zhang GZ, et al. Arch Med Sci. 2019 May 8;17(5):1213-1220. doi: 10.5114/aoms.2019.84888. eCollection 2021. Arch Med Sci. 2019. PMID: 34522250 Free PMC article. - Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.
Yeo D, Castelletti L, van Zandwijk N, Rasko JEJ. Yeo D, et al. Cancers (Basel). 2021 Aug 4;13(16):3932. doi: 10.3390/cancers13163932. Cancers (Basel). 2021. PMID: 34439085 Free PMC article. Review.
References
- Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 1992;52:181–6. - PubMed
- Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res. 2001;7:3862–8. - PubMed
- Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous